Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status (Ascending)
83634-0779-02 83634-0779 Metoclopramide hydrochloride Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous June 30, 2024 In Use
83703-0531-02 83703-0531 Palonosetron hydrochloride Palonosetron Hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Nov. 12, 2021 In Use
83831-0111-01 83831-0111 Pemetrexed dipotassium PEMETREXED DIPOTASSIUM 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 28, 2024 In Use
83831-0112-01 83831-0112 Pemetrexed dipotassium PEMETREXED DIPOTASSIUM 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 28, 2024 In Use
55513-0059-01 55513-0059 Tarlatamab-dlle IMDELLTRA (AMG757) 1.0 mg/1 Immunotherapy T Cell Receptor (TCR) DLL3, CD3 Intravenous May 16, 2024 In Use
81481-0803-01 81481-0803 Nogapendekin alfa inbakicept-pmln ANKTIVA 400.0 ug/.4mL Immunotherapy Cytokine IL-15 (⍺,β,ɣ) Intravesical May 6, 2024 In Use
82950-0001-16 82950-0001 TOVORAFENIB OJEMDA 100.0 mg/1 Chemotherapy Enzyme Inhibitor BRAF, CRAF Oral April 30, 2024 In Use
82950-0001-20 82950-0001 TOVORAFENIB OJEMDA 100.0 mg/1 Chemotherapy Enzyme Inhibitor BRAF, CRAF Oral April 30, 2024 In Use
82950-0001-24 82950-0001 TOVORAFENIB OJEMDA 100.0 mg/1 Chemotherapy Enzyme Inhibitor BRAF, CRAF Oral April 30, 2024 In Use
82950-0012-01 82950-0012 Tovorafenib OJEMDA 25.0 mg/ml Chemotherapy Enzyme Inhibitor BRAF, CRAF ORAL April 30, 2024 In Use

Found 10,000 results in 7 millisecondsExport these results